William Blair Boosts Earnings Estimates for Cooper Companies

The Cooper Companies, Inc. (NASDAQ:COO - Free Report) - William Blair increased their Q3 2025 earnings per share estimates for Cooper Companies in a research note issued on Friday, May 30th. William Blair analyst M. Andrew now expects that the medical device company will post earnings of $1.07 per share for the quarter, up from their prior estimate of $1.04. The consensus estimate for Cooper Companies' current full-year earnings is $3.98 per share. William Blair also issued estimates for Cooper Companies' Q4 2025 earnings at $1.11 EPS, FY2025 earnings at $4.07 EPS, Q1 2026 earnings at $1.01 EPS, Q2 2026 earnings at $1.05 EPS, Q3 2026 earnings at $1.17 EPS, Q4 2026 earnings at $1.22 EPS and FY2026 earnings at $4.45 EPS.

Cooper Companies (NASDAQ:COO - Get Free Report) last issued its quarterly earnings results on Thursday, May 29th. The medical device company reported $0.96 earnings per share for the quarter, beating analysts' consensus estimates of $0.93 by $0.03. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $995.12 million. During the same quarter in the previous year, the company posted $0.85 earnings per share. Cooper Companies's revenue for the quarter was up 6.3% compared to the same quarter last year.

Several other research analysts have also weighed in on the company. Robert W. Baird dropped their target price on Cooper Companies from $107.00 to $97.00 and set an "outperform" rating on the stock in a research report on Friday. Wells Fargo & Company dropped their target price on Cooper Companies from $118.00 to $93.00 and set an "overweight" rating on the stock in a research report on Friday. Needham & Company LLC reaffirmed a "hold" rating on shares of Cooper Companies in a research report on Thursday, May 22nd. JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $76.00 target price (down from $110.00) on shares of Cooper Companies in a research report on Friday. Finally, Stifel Nicolaus reduced their price target on Cooper Companies from $115.00 to $105.00 and set a "buy" rating for the company in a research report on Friday, March 7th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $100.38.

Cooper Companies Stock Down 1.9%

Shares of COO stock traded down $1.28 on Monday, reaching $67.00. 5,331,961 shares of the company's stock traded hands, compared to its average volume of 1,546,593. Cooper Companies has a 12-month low of $65.70 and a 12-month high of $112.38. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91. The company has a market capitalization of $13.40 billion, a P/E ratio of 34.36, a price-to-earnings-growth ratio of 2.25 and a beta of 1.08. The business's 50 day moving average price is $79.82 and its two-hundred day moving average price is $88.29.

Hedge Funds Weigh In On Cooper Companies

Several large investors have recently added to or reduced their stakes in COO. JPMorgan Chase & Co. raised its holdings in shares of Cooper Companies by 13.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,930,022 shares of the medical device company's stock worth $543,979,000 after buying an additional 573,908 shares in the last quarter. SG Americas Securities LLC raised its holdings in shares of Cooper Companies by 34.9% in the 4th quarter. SG Americas Securities LLC now owns 4,380 shares of the medical device company's stock worth $403,000 after buying an additional 1,134 shares in the last quarter. Exchange Traded Concepts LLC raised its holdings in shares of Cooper Companies by 17.9% in the 4th quarter. Exchange Traded Concepts LLC now owns 1,292 shares of the medical device company's stock worth $119,000 after buying an additional 196 shares in the last quarter. Blue Trust Inc. raised its holdings in shares of Cooper Companies by 26.3% in the 4th quarter. Blue Trust Inc. now owns 2,375 shares of the medical device company's stock worth $218,000 after buying an additional 494 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. raised its holdings in shares of Cooper Companies by 42.1% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,586 shares of the medical device company's stock worth $1,892,000 after buying an additional 6,102 shares in the last quarter. Institutional investors and hedge funds own 24.39% of the company's stock.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.